Reauthorizing improved generic and biosimilar user fee programs will lead to timelier approvals and lower drug costs. It's that simple.
Michael Burgess: “Reauthorizing improved generic and biosimilar user fee programs will lead to timelier approvals and lower drug costs.…”
Editor's note · Context
Burgess emphasizes the importance of user fee reauthorization for drug cost reduction.
Share
More from Michael Burgess
I am pleased to yield 4 minutes to the gentleman from Missouri (Mr. Alford) for his comments.
I urge all my fellow colleagues to join me in supporting H.R. 766 and ensuring that we continue to prioritize preventive healthcare initiatives for the betterment of all Americans, and I reserve the balance of my time.
I thank the gentleman for yielding additional time. However, one-sided pressure by the White House is not the way to ensure that end. Mr. Speaker, I urge passage of this rule from our committee, and I urge passage of the underlying…
For the purpose of debate only, I yield the customary 30 minutes to the Congresswoman from Pennsylvania (Ms. Scanlon), pending which I yield myself such time as I may consume. During consideration of this resolution, all time yielded is…





